Bernard J. Komoroski

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Bernard J. Komoroski, N. Vachharajani, L Li et al. · Clinical Pharmacology & Therapeutics · 2009 · 392 citations

Medicine, Pharmacology, Pharmacotherapy +17

Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450

Erin G. Schuetz, Stephen C. Strom, Kazuto Yasuda et al. · Journal of Biological Chemistry · 2001 · 391 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

Bernard J. Komoroski, N. Vachharajani, David W. Boulton et al. · Clinical Pharmacology & Therapeutics · 2009 · 346 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

Mary T. Obermeier, Ming Yao, Ashish Khanna et al. · Drug Metabolism and Disposition · 2009 · 181 citations

Medicine, Pharmacokinetics, Pharmacology +17

INDUCTION AND INHIBITION OF CYTOCHROMES P450 BY THE ST. JOHN’S WORT CONSTITUENT HYPERFORIN IN HUMAN HEPATOCYTE CULTURES

Bernard J. Komoroski, Shimin Zhang, Hongbo Cai et al. · Drug Metabolism and Disposition · 2004 · 180 citations

Medicine, Biochemistry, Pharmacology +17